These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 28737225)
21. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730 [TBL] [Abstract][Full Text] [Related]
22. Presynaptic effects of levodopa and their possible role in dyskinesia. Mosharov EV; Borgkvist A; Sulzer D Mov Disord; 2015 Jan; 30(1):45-53. PubMed ID: 25450307 [TBL] [Abstract][Full Text] [Related]
23. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F; J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
25. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
26. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. Evans AH; Lawrence AD; Lees AJ J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):267-72. PubMed ID: 18977820 [TBL] [Abstract][Full Text] [Related]
27. Management of motor fluctuations in Parkinson's disease. Koller WC Eur Neurol; 1996; 36 Suppl 1():43-8. PubMed ID: 8791022 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Cedarbaum JM Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267 [TBL] [Abstract][Full Text] [Related]
29. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution. Schelosky L; Poewe W Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415 [TBL] [Abstract][Full Text] [Related]
30. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389 [TBL] [Abstract][Full Text] [Related]
31. Clinical physiology of dopa dyskinesia. Hallett M Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic strategies to prevent motor complications in Parkinson's disease. Kieburtz K J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085 [TBL] [Abstract][Full Text] [Related]
33. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease. Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087 [TBL] [Abstract][Full Text] [Related]
34. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
35. Evidence-based initiation of dopaminergic therapy in Parkinson's disease. Miyasaki JM J Neurol; 2010 Nov; 257(Suppl 2):S309-13. PubMed ID: 21080195 [TBL] [Abstract][Full Text] [Related]
36. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Voon V; Fernagut PO; Wickens J; Baunez C; Rodriguez M; Pavon N; Juncos JL; Obeso JA; Bezard E Lancet Neurol; 2009 Dec; 8(12):1140-9. PubMed ID: 19909912 [TBL] [Abstract][Full Text] [Related]
37. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia. Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172 [TBL] [Abstract][Full Text] [Related]
38. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
39. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766 [TBL] [Abstract][Full Text] [Related]